BIOPLUS-INTERPHEX KOREA (BIX) 2026 is Korea's premier biopharmaceutical business event, bringing together global leaders across the entire biopharmaceutical value chain. Scheduled to take place from October 28-30, 2026, at COEX, Seoul, South Korea, the event serves as a platform for innovation, knowledge exchange, technology showcase, and strategic business partnerships.
From drug discovery and clinical development…
Shots:
Integer and KKR have entered into a definitive agreement under which an affiliate of investment funds managed by KKR will acquire Integer, delisting it from NYSE
As per the deal, KKR will acquire Integer in an all-cash transaction valued at $127 per share, representing the total enterprise value of ~$5.7B
As a KKR portfolio…
The pharmaceutical industry is entering a new era where innovation is no longer driven by individual organisations alone. From drug discovery and clinical research to manufacturing, regulatory compliance, digital transformation, and global commercialisation, success increasingly depends on strategic partnerships that combine expertise, technology, and shared ambition.
The Global Pharma Partnering Summit 2026 serves as a…
Shots:
Formycon and OneSource Specialty Pharma have entered into a strategic manufacturing partnership for biosimilars
As per the deal, OneSource will act as Formycon’s strategic manufacturing partner, providing integrated Drug Substance (DS) and Drug Product (DP) manufacturing from its advanced biologics facility in Bangalore, India
The collaboration combines Formycon’s biosimilar development expertise with OneSource’s end-to-end biologics manufacturing capabilities to advance Formycon’s global biosimilar programs
Ref: Formycon | Image:…
Shots:
Piramal Pharma Solutions has entered into a strategic collaboration with Ajinomoto Bio-Pharma Services to support antibody-drug conjugate (ADC) development and manufacturing programs
Under the agreement, Piramal will refer customers to Ajinomoto’s AJICAP platform for site-specific ADC conjugation, while Ajinomoto will direct clients to Piramal for CDMO manufacturing services across development and commercialization
The collaboration…
Shots:
Lonza has agreed to divest its Capsules & Health Ingredients (CHI) business to Lone Star Funds for an enterprise value of CHF 2.3B (~$3B), receiving CHF 1.7B (~$2.2B) upfront while retaining a 40% stake with preferential participation in future exit proceeds
Lonza is expecting total undiscounted proceeds of ≥CHF 3B (~$4B) from CHI via…
Shots:
EirGenix has entered into a strategic collaboration and non-exclusive licensing agreement with Transcenta for its Highly Intensified Continuous Bioprocessing (HiCB) platform
Under the agreement, Transcenta will grant EirGenix a non-exclusive license to its HiCB platform, incl. continuous perfusion & integrated hybrid continuous purification process technologies, as well as documentation, know-how & regulatory support to…
Shots:
Samsung Biologics’ US subsidiary entered a definitive agreement to acquire 100% of Human Genome Sciences from GSK, securing its first US based manufacturing site in Rockville, Maryland
As per the deal terms, Samsung Biologics will acquire the Rockville assets for $280M, with closing expected by end of Q1’26, while retaining 500+ employees to ensure…
Shots:
Thermo Fisher has entered into a definitive agreement to acquire Clario, enhancing its digital & data capabilities in clinical research
As per the deal, Thermo Fisher Scientific will acquire Clario for $8.875B in cash, with an additional $125M due in January 2027 & ~$400M in performance-based earnouts for 2026–2027; closing is expected mid-2026, after…
BioPharma Deals: The Survival Series brings together leaders from biotech, pharma, investment, CRO/CDMO, legal, and advisory sectors for a high-impact event focused on pragmatic deal-making, new financing models, early IPOs, and unconventional partnerships.
This is not a conference about the distant future. It's a working summit for what can be done now. It's about survival,…

